Antifibrotic Effects of Aldosterone Receptor Blocker (Spironolactone) in Patients with Chronic Kidney Disease
| العنوان: | Antifibrotic Effects of Aldosterone Receptor Blocker (Spironolactone) in Patients with Chronic Kidney Disease |
|---|---|
| المؤلفون: | Ibrahim Guney, M. Kemal Basarali, N. Yılmaz Selçuk, Huseyin Atalay, Lutfullah Altintepe, Sadık Büyükbaş |
| المساهمون: | Selçuk Üniversitesi |
| بيانات النشر: | TAYLOR & FRANCIS LTD, 2009. |
| سنة النشر: | 2009 |
| مصطلحات موضوعية: | Adult, Male, Adrenergic Antagonists, medicine.medical_specialty, medicine.drug_class, Aldosterone escape, Urology, Angiotensin-Converting Enzyme Inhibitors, Critical Care and Intensive Care Medicine, Transforming Growth Factor beta1, chemistry.chemical_compound, Mineralocorticoid receptor, Internal medicine, medicine, Humans, Prospective Studies, Mineralocorticoid Receptor Antagonists, Aldosterone, business.industry, Glomerulosclerosis, General Medicine, Middle Aged, medicine.disease, Fibrosis, Endocrinology, spironolactone, chemistry, Nephrology, Mineralocorticoid, Potassium-sparing diuretic, Disease Progression, Spironolactone, Kidney Failure, Chronic, Female, proteinuria, business, TGF-beta 1, chronic kidney disease, Kidney disease |
| الوصف: | WOS: 000273987900002 PubMed: 19925284 Aims. Proteinuria and transforming growth factor beta (TGF-beta) are parameters that can lead to glomerulosclerosis and tubulointerstitial fibrosis. All components of the renin-angiotensin-aldosterone system (RAAS) activate the TGF-beta. Aldosterone may not be inhibited with angiotensin-converting enzyme inhibitors (ACEIs) and/or angiotensin receptor blockers (ARBs) due to aldosterone escape. We aimed to evaluate the effect of spironolactone on parameters leading to fibrosis. Methods. This prospective study included 30 non-diabetic chronic kidney disease (CKD) patients treated with ACEIs and/or ARBs. The patients were divided into two groups that are similar in terms of demographic parameters. 25 mg of spironolactone was added to group 1 (n = 15) for six months, though it was not administered to group 2 (n = 15). Creatinine (U-Cr), protein (U-Prot), and TGF-beta 1 (U-TGF-beta 1) were measured in spot urine sample in the beginning of study and six months later. Results. Twenty-four patients completed the study. There were no significant changes in mean blood pressure, glomerular filtration rate, creatinine, albumin, and plasma aldosterone concentrations during the observation period in either group. U-Prot/U-Cr (mg/mg Cr) was reduced from 2.43 +/- 4.85 at baseline to 1.66 +/- 3.51 at sixth month (p = 0.003) in group 1. In addition, U-TGF-beta 1/U-Cr (ng/mg Cr) was also reduced from 22.50 +/- 6.65 at baseline to 17.78 +/- 10.94 at sixth month (p = 0.041) in the same group. U-TGF-beta 1/U-Cr and U-Prot/U-Cr ratios after the sixth month were not found significant compared with baseline values in group 2. Conclusion. Spironolactone reduced both proteinuria and urinary TGF-beta 1 excretion in CKD patients. We consider that spironolactone would be beneficial to prevent progression of renal fibrosis in CKD. Ali Raif Drug Industry A.C. This study was supported by Ali Raif Drug Industry A.C. for providing TGF-beta 1 and aldosterone kits. |
| اللغة: | English |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f756b9a76f3c135b834003813eb952b6Test https://hdl.handle.net/20.500.12395/23284Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....f756b9a76f3c135b834003813eb952b6 |
| قاعدة البيانات: | OpenAIRE |
| الوصف غير متاح. |